Table 4.
Replication of HLA types associated with sulfasalazine‐induced agranulocytosis
| HLA allele | N | N Case | N Control | MAF Case | MAF Control | OR | 95% CI | C Stat | P |
|---|---|---|---|---|---|---|---|---|---|
| C*14:02 | 182 | 40 | 142 | 0.00 | 0.00 | N/A | |||
| B*08:01 | 182 | 40 | 142 | 0.16 | 0.09 | 2.25 | [1.02, 4.97] | 0.574 | 0.0439 |
| Full haplotype | 182 | 40 | 142 | 0.16 | 0.06 | 3.79 | [1.63, 8.80 | 0.606 | 0.0019 |
| C*02:02 | 182 | 40 | 142 | 0.09 | 0.09 | 0.99 | [0.39, 2.50] | 0.501 | 0.9876 |
| B*07:02 | 182 | 40 | 142 | 0.19 | 0.12 | 1.67 | [0.84, 3.28] | 0.571 | 0.1406 |
| A*31:01 | 182 | 40 | 142 | 0.09 | 0.02 | 4.81 | [1.52, 15.26] | 0.566 | 0.0077 |
The HLA types were selected by sequential adjustment for each significant association in the discovery cohort. Associated HLA types were compared between replication cases and controls treated 90 days or more using logistic regression. The effect was modeled per increase of one present HLA type. The full haplotype is HLA‐DQB1*02:01‐DRB1*03:01‐B*08:01‐C*07:01.
N = number, OR = odds ratio, 95% CI = 95% confidence interval, C Stat = C statistic, N/A = not available.